Study Summary
This trial is studying two different combinations of drugs to see which is better at treating patients with advanced gastric or gastroesophageal junction cancer.
- Stage III Gastric Cancer
- Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma
- Stage IVB Gastric Cancer
- Metastatic Gastric Cancer
- Stage IIIB Gastric Cancer
- Stage IIIA Gastric Cancer
- Postneoadjuvant Therapy Stage III Gastric Cancer
- Stage IVA Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer
- Postneoadjuvant Therapy Stage IV Gastric Cancer
- Stage IV Gastric Cancer
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma
- Stage IV Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma
- Clinical Stage IV Gastroesophageal Junction Adenocarcinoma
- Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma
- Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma
- Pathologic Stage III Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma
- Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Up to 3 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Arm B (paclitaxel, ramucirumab)
1 of 2
Arm A (TAS-102, ramucirumab)
1 of 2
Active Control
Experimental Treatment
116 Total Participants · 2 Treatment Groups
Primary Treatment: Quality-of-Life Assessment · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What are some risks associated with Quality-of-Life Assessment?
"While there is some data supporting the safety of Quality-of-Life Assessment, it received a score of 2 because this is only a Phase 2 trial and thus there is no efficacy data." - Anonymous Online Contributor
Could you please share some similar studies to the Quality-of-Life Assessment clinical trial?
"At this moment, 942 clinical trials regarding Quality-of-Life Assessment are ongoing with 242 in Phase 3. Even though a large quantity of the research for Quality-of-Life Assessment is based in Woolloongabba, Queensland, there are still 48357 other locations conducting these studies." - Anonymous Online Contributor
How many different hospitals are running this clinical trial?
"This study is currently enrolling patients at 11 sites across the United States of America. If you are considering participating in this trial, it would be most convenient to select a site near your location to minimize travel requirements." - Anonymous Online Contributor
What do doctors hope to learn from Quality-of-Life Assessments?
"Quality-of-Life Assessment can be used to treat patients with ras wild-type, who have a history of anti-egfr therapy, and are suffering from locally advanced non-small cell lung cancer or metastatic bladder cancer." - Anonymous Online Contributor
Are there any current vacancies for this clinical trial?
"Yes, according to the information on clinicaltrials.gov, this study is looking for participants. The trial was first posted on 6/16/2021 and updated on 4/4/2022. There are 11 locations enrolling a total of 116 patients." - Anonymous Online Contributor
How many test subjects are part of this experiment?
"The clinical trial is, as of now, recruiting patients from 11 different centres with the goal to enroll 116 individuals in total. The study was first posted on June 16th, 2021 and most recently updated on April 4th, 2022 according to data available on clinicaltrials.gov" - Anonymous Online Contributor